A Phase 3, Randomized, Double-blind Clinical Study to Evaluate the Long-term Safety and Efficacy of MK-7264 in Japanese Adult Participants With Refractory or Unexplained Chronic Cough
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Gefapixant (Primary)
- Indications Cough
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme
- 26 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Nov 2018 Planned primary completion date changed from 1 Oct 2020 to 6 Oct 2020.
- 12 Nov 2018 Status changed from not yet recruiting to recruiting.